OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of RNA interference (RNAi) therapeutics. The company utilizes its proprietary OASIS (OliX Advanced Small Interfering RNA System) platform, which includes cell-penetrating asymmetric siRNA (cp-asiRNA) technology, to develop locally and systemically administered treatments for diseases with high unmet medical needs. OliX focuses on a broad range of therapeutic areas, including ophthalmology (e.g., wet AMD), dermatology (e.g., hypertrophic scars, hair loss), and liver-related metabolic disorders (e.g., MASH, obesity). The company maintains a global presence with its headquarters in South Korea and research/clinical operations in the United States and Australia, supported by strategic partnerships with global leaders like L'Oréal and Hansoh Pharma.